Shandong Weigao Group Medical Polymer Company Limited (WEIGAO GROUP, HKEX: 01066) disclosed on 8 October 2026 that it repurchased 149,200 H shares on the Hong Kong Stock Exchange at prices ranging between HKD 3.25 and HKD 3.27 per share, for a volume-weighted average cost of HKD 3.2621. The total consideration amounted to HKD 0.49 million.

Following the transaction, the company’s issued share capital (excluding treasury shares) declined marginally by 0.0033% to 4.46 billion shares. Treasury shares increased to 67.07 million, while the total issued share count remained unchanged at 4.52 billion.

The buyback was executed under the general mandate approved by shareholders on 29 May 2026, which authorises the company to repurchase up to 446.46 million shares. Cumulative purchases under this mandate now stand at 9.75 million shares, representing 2.18% of the issued share base on the mandate date, leaving roughly 436.72 million shares available for further repurchase.

All 149,200 repurchased shares are being held as treasury stock; no cancellations have been effected to date. In line with Hong Kong listing rules, WEIGAO GROUP is subject to a 30-day moratorium—until 8 November 2026—on issuing new shares or disposing of any treasury shares following the buyback.

The disclosure was signed by Company Secretary Phillis Wong and confirms that all repurchase activities complied with Hong Kong Stock Exchange regulations and the company’s authorised mandate.